Pictor Raises $7.5 Million Bridge Round to Accelerate Targeted Proteomic Platform Commercialization. The funding will enhance partnerships and platform development.
Pictor Holdings announced the closure of a $7.5 million bridge round of growth capital. The financing will help expand commercial partnerships, scale development, and support translational studies in human and animal health. This round increases Pictor's total capital raised to approximately $30 million. The company is also evaluating a U.S.-based Series A financing for future growth.
Company Information
Company
Pictor
Location
Auckland, Auckland, New Zealand
About
Pictor is an in vitro diagnostics company that offers a patented multiplexed platform for highly accurate and efficient testing of complex and infectious diseases for human and animal health. PictArray™ multiplexed technology makes it possible to test multiple disease markers in a single test simultaneously — with higher sensitivity, faster throughput, and reduced turn-around time. The company’s lead product, the PictArray™ SARS-CoV-2 IgG ELISA Kit, enables more informed clinical intervention to manage the threat of COVID-19. For more information, please visit http://pictordx.com, https://www.linkedin.com/company/pictorltd and @PictorLtd on Twitter or Facebook.
Fundz sees it the moment Pictor raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
AucklandBiotechnologyHealth CareTherapeuticsHealth Diagnostics